{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "May 2018: 81-year-old female presented with productive cough and shortness of breath for several months. Chest CT scan showed a 58 mm \u00d7 62 mm nodule in the left lung with multiple small nodules, enlarged mediastinal lymph nodes, and pleural effusions. Diagnosed with stage IV lung adenocarcinoma.",
        "clinical_data": {
          "HPI": [
            {
              "summary": "Productive cough and shortness of breath for several months",
              "duration": "several months"
            }
          ],
          "imaging": [
            {
              "type": "Lung mass",
              "body_part": "Lung",
              "modality": "CT",
              "finding": "58 mm \u00d7 62 mm nodule in the left lung with multiple small nodules, enlarged mediastinal lymph nodes, and pleural effusions",
              "date": "2018-05"
            }
          ],
          "diagnoses": [
            {
              "code": "C0242398",
              "label": "stage IV lung adenocarcinoma",
              "status": "active",
              "onset_date": "2018-05"
            }
          ]
        },
        "timestamp": "2018-05"
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Capture-based next-generation sequencing (NGS) with a panel of 168 cancer-related genes (Lung Plasma, Burning Rock, Guangzhou, China) was conducted with a lung biopsy specimen. Identified EGFRc.2236_2250del (p.E746_A750del) mutation (abundance 11.52%).",
        "clinical_data": {
          "labs": [
            {
              "test": "Next Generation Sequencing",
              "value": "EGFRc.2236_2250del (p.E746_A750del) mutation (abundance 11.52%)",
              "unit": "%",
              "flag": "abnormal",
              "timestamp": null
            }
          ],
          "diagnoses": [
            {
              "code": "C4972",
              "label": "EGFR mutation positive",
              "status": "active",
              "onset_date": null
            }
          ]
        },
        "timestamp": "2018-05"
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Started on osimertinib (80 mg, qd) as the first-line therapy. Symptoms improved rapidly. Chest CT evaluation 12 weeks later showed a partial response (PR) and the lung lesion significantly decreased (38 mm \u00d7 22 mm).",
        "clinical_data": {
          "medications": [
            {
              "drug": "Osimertinib",
              "dosage": "80 mg",
              "frequency": "qd",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": "first-line therapy"
            }
          ],
          "imaging": [
            {
              "type": "Lung lesion",
              "body_part": "Lung",
              "modality": "CT",
              "finding": "Partial response (PR), lesion significantly decreased (38 mm \u00d7 22 mm)",
              "impression": "Partial response",
              "date": null
            }
          ],
          "HPI": [
            {
              "summary": "Symptoms improved rapidly",
              "duration": null,
              "onset": null,
              "progression": null,
              "associated_symptoms": [],
              "alleviating_factors": [],
              "exacerbating_factors": []
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "After 11 months of disease control, a CT scan showed an enlarged left lung mass (66 mm \u00d7 50 mm). Ultra-deep plasma-derived circulating tumor DNA (ctDNA) NGS revealed EGFRE746_A750del (abundance 0.54%) and TP53H179R mutation (abundance 1.32%). Patient presented asymptomatic disease progression (PD) and refused chemotherapy, so she continued osimertinib treatment (80 mg, qd).",
        "clinical_data": {
          "imaging": [
            {
              "type": "CT scan",
              "body_part": "left lung",
              "modality": "CT",
              "finding": "enlarged mass (66 mm \u00d7 50 mm)"
            }
          ],
          "labs": [
            {
              "test": "Ultra-deep plasma-derived circulating tumor DNA (ctDNA) NGS",
              "value": "EGFRE746_A750del (abundance 0.54%) and TP53H179R mutation (abundance 1.32%)"
            }
          ],
          "diagnoses": [
            {
              "code": "disease progression",
              "label": "disease progression",
              "status": "active"
            }
          ],
          "medications": [
            {
              "drug": "Osimertinib",
              "dosage": "80 mg",
              "frequency": "qd"
            }
          ],
          "HPI": [
            {
              "summary": "asymptomatic disease progression"
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "clinical_data": {}
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Lung biopsy specimen sent for capture-based next-generation sequencing (NGS) with a panel of 168 cancer-related genes (Lung Plasma, Burning Rock, Guangzhou, China)."
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Initiation of osimertinib (80 mg, qd) as the first-line therapy.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0000000"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "After 11 months of disease control, CT scan showed an enlarged left lung mass (66 mm \u00d7 50 mm). Ultra-deep plasma-derived circulating tumor DNA (ctDNA) NGS revealed EGFRE746_A750del (abundance 0.54%) and TP53H179R mutation (abundance 1.32%). Patient presented asymptomatic disease progression (PD) and refused chemotherapy, so she continued osimertinib treatment (80 mg, qd).",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [],
          "change_type": "progression",
          "target_domain": "imaging"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "No new information provided."
      }
    }
  ]
}